UY34880A - Preparación líquida - Google Patents
Preparación líquidaInfo
- Publication number
- UY34880A UY34880A UY0001034880A UY34880A UY34880A UY 34880 A UY34880 A UY 34880A UY 0001034880 A UY0001034880 A UY 0001034880A UY 34880 A UY34880 A UY 34880A UY 34880 A UY34880 A UY 34880A
- Authority
- UY
- Uruguay
- Prior art keywords
- liquid preparation
- pharmaceutically active
- active principle
- amino group
- organic acid
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 3
- 150000007524 organic acids Chemical class 0.000 abstract 2
- 150000001408 amides Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D3/00—Halides of sodium, potassium or alkali metals in general
- C01D3/04—Chlorides
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D3/00—Halides of sodium, potassium or alkali metals in general
- C01D3/10—Bromides
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
- C01F11/20—Halides
- C01F11/24—Chlorides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Geology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan una preparación líquida en donde el principio farmacéuticamente activo es estabilizado, y un método estabilizante para ello. Una prep aración líquida que comprende un principio farmacéuticamente activo con un grupo amino primario o secundario (en donde el grupo amino no constituye una parte de la estructura de amida), un ácido orgánico y una sal, que está sustancialmente libre de un producto de reacción del principio farmacéuticamente activo y el ácido orgánico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012144750 | 2012-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34880A true UY34880A (es) | 2014-01-31 |
Family
ID=48795873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001034880A UY34880A (es) | 2012-06-27 | 2013-06-26 | Preparación líquida |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20150165027A1 (es) |
| EP (1) | EP2866788B1 (es) |
| JP (1) | JP6216338B2 (es) |
| KR (1) | KR102206928B1 (es) |
| CN (3) | CN110200903B (es) |
| AR (1) | AR091567A1 (es) |
| AU (1) | AU2013281626A1 (es) |
| BR (1) | BR112014031282A2 (es) |
| CA (1) | CA2877619C (es) |
| HK (1) | HK1209338A1 (es) |
| IL (1) | IL236187A0 (es) |
| MX (1) | MX2014015269A (es) |
| NZ (1) | NZ703528A (es) |
| PH (1) | PH12014502863A1 (es) |
| RU (1) | RU2015102333A (es) |
| SG (1) | SG11201408511QA (es) |
| TW (1) | TWI623327B (es) |
| UY (1) | UY34880A (es) |
| WO (1) | WO2014003199A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105982867A (zh) * | 2015-02-27 | 2016-10-05 | 江苏柯菲平医药股份有限公司 | 一种h009冻干粉针及其制备方法 |
| CN104814964B (zh) * | 2015-04-16 | 2018-07-31 | 广东赛烽医药科技有限公司 | 一种抗胃幽门螺旋杆菌的药物组合物、制备方法及其应用 |
| CN106265535A (zh) * | 2015-06-23 | 2017-01-04 | 中美华世通生物医药科技（武汉）有限公司 | 富马酸沃诺拉赞冻干粉针制剂及其制备方法 |
| CN104926790B (zh) * | 2015-06-29 | 2017-07-07 | 江苏奥赛康药业股份有限公司 | 一种高纯度Vonoprazan Fumarate化合物及其中间体、杂质以及它们的制备方法 |
| CN106511344A (zh) * | 2015-09-14 | 2017-03-22 | 王虹 | 一种胃酸分泌抑制剂的新用途 |
| RU2657833C2 (ru) * | 2015-12-01 | 2018-06-15 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение |
| CN105640877A (zh) * | 2016-01-26 | 2016-06-08 | 北京阜康仁生物制药科技有限公司 | 一种含有沃诺拉赞的液体制剂 |
| CN107525877B (zh) * | 2016-06-20 | 2021-08-03 | 重庆医药工业研究院有限责任公司 | 一种采用液相色谱法分离测定依匹哌唑及其杂质的方法 |
| EA030671B1 (ru) * | 2016-07-20 | 2018-09-28 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Препарат для лечения костных поражений, вызванных злокачественными новообразованиями |
| CN107536801B (zh) * | 2017-08-18 | 2019-08-06 | 常州兰陵制药有限公司 | 氯化钙溴化钠注射液的制备工艺 |
| CN108689991B (zh) * | 2018-06-11 | 2019-12-20 | 杭州中美华东制药有限公司 | 沃诺拉赞新晶型盐及其制备方法 |
| CN110917201A (zh) * | 2019-12-02 | 2020-03-27 | 吉林省博大伟业制药有限公司 | 聚普瑞锌在制备治疗萎缩性胃炎伴随胃粘膜上皮异型增生的药物中的应用 |
| CN113350271A (zh) * | 2020-03-04 | 2021-09-07 | 广东东阳光药业有限公司 | 一种质子泵抑制剂的组合物及其制备方法 |
| AU2021293694B2 (en) * | 2020-06-17 | 2023-12-21 | Ildong Pharmaceutical Co., Ltd. | Novel Acid Secretion Inhibitor and use thereof |
| CN111943932B (zh) * | 2020-08-06 | 2023-07-14 | 四川国康药业有限公司 | 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途 |
| CN116270443A (zh) * | 2022-10-27 | 2023-06-23 | 广州白云山天心制药股份有限公司 | 富马酸伏诺拉生注射液及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19833119A1 (de) * | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Spritzfertige Injektionslösungen enthaltend Carvedilol |
| ES2305065T3 (es) * | 2000-04-24 | 2008-11-01 | Daiichi Sankyo Company, Limited | Preparacion liquida estable que contiene sitafloxacina. |
| MY137726A (en) * | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| CA2473412A1 (en) * | 2004-07-08 | 2006-01-08 | Laboratoires Omega Ltee | Liquid pharmaceutical injectable formulation of octreotide |
| EP2336107B1 (en) | 2004-09-30 | 2015-09-23 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| PL1919865T3 (pl) * | 2005-08-30 | 2011-09-30 | Takeda Pharmaceuticals Co | 1-heterocyklilosulfonylo, 2-aminometylo, 5-(hetero-) arylo podstawione pochodne 1-h-pirolu jako kwasowe inhibitory wydzielania |
| WO2007114338A1 (ja) | 2006-03-31 | 2007-10-11 | Takeda Pharmaceutical Company Limited | 酸分泌抑制薬 |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| US8658183B2 (en) * | 2007-08-09 | 2014-02-25 | Taigen Biotechnology Company, Ltd. | Antimicrobial parenteral formulation |
| EP3162798B1 (en) | 2007-09-28 | 2021-04-14 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compound |
| CL2008002834A1 (es) | 2007-09-28 | 2009-09-11 | Takeda Pharmaceuticals Co | Compuestos heterociclicos de 5 miembros, composicion farmaceutica, util para el tratamiento de la ulcera peptidica, sindrome de zollinger-ellison, gastritis, esofagitis por reflujo, enfermedad sintomatica por reflujo gastroesofagico, esofago de barrett, cancer gastrico, hiperacidez gastrica o ulcera debido a estres posquirurgico. |
| US9186411B2 (en) * | 2008-07-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
| AU2009284867B2 (en) | 2008-08-27 | 2014-08-28 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| NZ595890A (en) | 2009-03-26 | 2013-09-27 | Takeda Pharmaceutical | Pyrazole compound |
-
2013
- 2013-06-26 CN CN201910298076.XA patent/CN110200903B/zh active Active
- 2013-06-26 KR KR1020157002034A patent/KR102206928B1/ko active IP Right Grant
- 2013-06-26 NZ NZ703528A patent/NZ703528A/en not_active IP Right Cessation
- 2013-06-26 WO PCT/JP2013/068192 patent/WO2014003199A1/en active Application Filing
- 2013-06-26 TW TW102122662A patent/TWI623327B/zh active
- 2013-06-26 AR ARP130102255 patent/AR091567A1/es unknown
- 2013-06-26 CN CN201380044649.7A patent/CN104582687A/zh active Pending
- 2013-06-26 SG SG11201408511QA patent/SG11201408511QA/en unknown
- 2013-06-26 UY UY0001034880A patent/UY34880A/es not_active Application Discontinuation
- 2013-06-26 CA CA2877619A patent/CA2877619C/en active Active
- 2013-06-26 MX MX2014015269A patent/MX2014015269A/es unknown
- 2013-06-26 US US14/407,174 patent/US20150165027A1/en not_active Abandoned
- 2013-06-26 JP JP2014561221A patent/JP6216338B2/ja active Active
- 2013-06-26 EP EP13737879.0A patent/EP2866788B1/en active Active
- 2013-06-26 CN CN201911035338.XA patent/CN110917130A/zh active Pending
- 2013-06-26 BR BR112014031282A patent/BR112014031282A2/pt not_active IP Right Cessation
- 2013-06-26 RU RU2015102333A patent/RU2015102333A/ru not_active Application Discontinuation
- 2013-06-26 AU AU2013281626A patent/AU2013281626A1/en not_active Abandoned
-
2014
- 2014-12-11 IL IL236187A patent/IL236187A0/en unknown
- 2014-12-22 PH PH12014502863A patent/PH12014502863A1/en unknown
-
2015
- 2015-10-15 HK HK15110093.8A patent/HK1209338A1/xx unknown
-
2022
- 2022-12-16 US US18/082,799 patent/US20230143246A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI623327B (zh) | 2018-05-11 |
| NZ703528A (en) | 2016-08-26 |
| PH12014502863A1 (en) | 2015-02-23 |
| CA2877619A1 (en) | 2014-01-03 |
| CN110200903A (zh) | 2019-09-06 |
| KR20150023883A (ko) | 2015-03-05 |
| BR112014031282A2 (pt) | 2017-06-27 |
| TW201406399A (zh) | 2014-02-16 |
| SG11201408511QA (en) | 2015-01-29 |
| HK1209338A1 (en) | 2016-04-01 |
| CN104582687A (zh) | 2015-04-29 |
| US20150165027A1 (en) | 2015-06-18 |
| EP2866788A1 (en) | 2015-05-06 |
| CN110200903B (zh) | 2022-07-29 |
| US20230143246A1 (en) | 2023-05-11 |
| WO2014003199A1 (en) | 2014-01-03 |
| AR091567A1 (es) | 2015-02-11 |
| IL236187A0 (en) | 2015-01-29 |
| JP6216338B2 (ja) | 2017-10-18 |
| KR102206928B1 (ko) | 2021-01-22 |
| MX2014015269A (es) | 2015-02-20 |
| RU2015102333A (ru) | 2016-08-20 |
| JP2015521986A (ja) | 2015-08-03 |
| AU2013281626A1 (en) | 2015-01-22 |
| CA2877619C (en) | 2020-09-22 |
| EP2866788B1 (en) | 2020-12-16 |
| CN110917130A (zh) | 2020-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34880A (es) | Preparación líquida | |
| AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
| PE20141672A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| BR112017001427A2 (pt) | sistema de fornecimento de aerossol | |
| AR088379A1 (es) | Formulaciones de etanercept estabilizadas con iones metalicos | |
| PE20150200A1 (es) | Formulacion de anticuerpos | |
| ECSP11010855A (es) | Composición farmacéutica | |
| EA201590953A1 (ru) | Пирролидиновые модуляторы gpr40 | |
| AR085155A1 (es) | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos | |
| EA033811B1 (ru) | Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций | |
| CL2014001315A1 (es) | Pestaña de apertura facil, comprende un primer ensanchamiento configurado para que se extienda desde un remache de atado central de un envase hasta un primer punto adyacente a la circunferencia del envase, un segundo ensanchamiento, un arco configurado para que se extienda desde el primer punto adyacente a la circunferencia del envase hasta un segundo punto, un cuerpo definido mediante el primer ensanchamiento; metodo. | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| CU20120137A7 (es) | Hidrato del hidrocloruro de agomelatina y preparación de éste | |
| MX2017006709A (es) | Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales. | |
| AR100365A1 (es) | Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla | |
| CL2016000027A1 (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. | |
| AR113288A2 (es) | Producto, método para producirlo, método para insertar un accesorio en un cuello de un recipiente y producto fabricado por el mismo | |
| TN2012000516A1 (en) | Stable ready to use injectable paracetamol formulation | |
| BR112014029264A2 (pt) | microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo | |
| MY178705A (en) | Method of preparing broad spectrum vaccine for preventing avian colibacillosis | |
| CU20120136A7 (es) | Hidrato del hidrobromuro de agomelatina y preparación de éste | |
| EA201400473A1 (ru) | Способ синтеза 3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбонитрила и применение для синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой | |
| MX369244B (es) | Solucion alcoholica estable de alprostadilo. | |
| CL2017003383A1 (es) | Procedimiento para la producción de urea sólida por granulación. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20140715 |